Aβ conformer selective anti-Aβ globulomer monoclonal antibodies

• US 9,394,360 B2
• Filed: 10/14/2014
• Issued: 07/19/2016
• Est. Priority Date: 11/30/2006
• Status: Active Grant

• Current Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated)
• Original Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated), Abbvie Incorporated
• Inventors: Barghorn, Stefan, Hillen, Heinz, Striebinger, Andreas R., Labkovsky, Boris, Ebert, Ulrich, Keller, Patrick
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US14/513,837
• Publication Number:
  US 20150175684A1
• Time in Patent Office: 644 Days
• US Class Current: 1/1
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/10 characterized by their source of isolation or production
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer'"'"'s Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.

Claims

1. A method of diagnosing Alzheimer'"'"'s Disease in a patient suspected of having this disease comprising the steps of:

a. isolating a biological sample from said patient;

b. contacting said biological sample with an isolated antibody for a time and under conditions sufficient for formation of antigen/antibody complexes, wherein the isolated antibody comprises;

(i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO;

5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO;

6 or

(ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO;

7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO;

8; and

c. detecting presence of said antigen/antibody complexes in said sample, whereby the presence of said complexes indicates a diagnosis of Alzheimer'"'"'s Disease in said patient.

2. The method of claim 1 wherein said antigen is a globulomer.